Clinical Trials Search Results
- A Multi-Center Observational Study: The RECOVER Post Acute Sequelae of SARS-CoV-2 (PASC) Pediatric Cohort Study
Research efforts focus on the long-term effects of COVID-19, called Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Long COVID is a form of PASC, and refers to symptoms that persist for weeks or months after the acute infection. Research teams, including the Avera Research Institute, study and share data in real time, providing the scale needed to get answers to help alleviate suffering as fast as possible.
- A Phase 2/3, Interventional safety, pharmacokinetics, and efficacy, open-label, multi-center, single-arm study to investigate orally administered PF-07321332 (Nirmatrelvir)/Ritonavir in non-hospitalized symptomatic pediatric participants with COVID-19 who are at risk of progression to severe disease
To compare the efficacy of nirmatrelvir (PF-07321332)/ritonavir to placebo for the treatment of symtomatic COVID-19 in non- hospitalized pediatric participants with COVID-19 who are at risk of progression to severe disease. Patients are randomized 1:1 and will receive placebo or the investigational product orally for 5 days. Patients will complete in-person and remote follow-up visits including assessments such as nasapharyngeal swabs, blood draws, and physical exams. Participants will be compensated for their time.
- A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine when Administered Concomitantly with GSK Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects 16-18 Years of Age.
Meningococcal Group B Vaccine trial for teens, ages 16-18 years.
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
The study investigators are interested in learning more about how drugs act in the bodies of children and young adults in hopes to find the most safe and effective dose for children.
